Paul Tudor Jones's NAMS Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 79,460 shares of NewAmsterdam Pharma Company N.V. (NAMS) worth $2.69 M, representing 0.00% of the portfolio. First purchased in 2024-Q4, this short-term holding has been held for 3 quarters.
Based on 13F filings, Paul Tudor Jones has maintained this position in NAMS for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 79,460 shares. Largest reduction occurred in Q1 2025, reducing 52,208 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's NewAmsterdam Pharma Company NV (NAMS) Holding Value Over Time
Track share changes against reported price movement
Quarterly NewAmsterdam Pharma Company NV (NAMS) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +79,460 | New Buy | 79,460 | $33.89 |
| Q1 2025 | -52,208 | Sold Out | 0 | $0.00 |
| Q4 2024 | +52,208 | New Buy | 52,208 | $25.70 |
Paul Tudor Jones's NewAmsterdam Pharma Company NV Investment FAQs
Paul Tudor Jones first purchased NewAmsterdam Pharma Company N.V. (NAMS) in Q4 2024, acquiring 52,208 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held NewAmsterdam Pharma Company N.V. (NAMS) for 3 quarters since Q4 2024.
Paul Tudor Jones's largest addition to NewAmsterdam Pharma Company N.V. (NAMS) was in Q2 2026, adding 79,460 shares worth $2.69 M.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 79,460 shares of NewAmsterdam Pharma Company N.V. (NAMS), valued at approximately $2.69 M.
As of the Q2 2026 filing, NewAmsterdam Pharma Company N.V. (NAMS) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in NewAmsterdam Pharma Company N.V. (NAMS) was 79,460 shares, as reported at the end of Q2 2026.